Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 1

Recruiting

• Conditions: Solid tumors; MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2023-507418-28-00
• Lead Sponsor: F. Hoffmann-La Roche AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-06-10
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 825

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy, Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC), Performance status as follows: Participants aged = 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participants aged 16 to < 18 years: Karnofsky score = 50%; Participants aged < 16 years: Lansky score = 50%, For participants aged = 18 and <18 years: adequate hematologic and end-organ function, Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment, Adequate recovery from most recent systemic or local treatment for cancer

Exclusion Criteria

Current participation or enrollment in another therapeutic clinical trial, Any anticancer treatment within 2 weeks prior to start of study treatment (Please refer to the cohort-specific eligibility criteria for requirements on enrollment, if applicable), Whole brain radiotherapy within 14 days prior to start of study treatment, Stereotactic radiosurgery within 7 days prior to start of study treatment, Pregnant or breastfeeding, or intending to become pregnant during the study, History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified